Paolo Tarantino: More data supporting that ADCs act in part by extending the half life of payloads
Paolo Tarantino shared a post by Raffaele Colombo on X, adding the following:
“More data supporting the hypothesis that ADCs act in part by extending the half life of payloads
This leads to prolonged exposure of the tumor to the payload, with activity irrespective of target exp
E.g. DV with similar ORR in HER2+/-low, SG with similar ORR in Trop2-high/low.”
Quoting Raffaele Colombo’s post:
“Disitamab vedotin, in patients with HER2-overexpression and HER2-low breast cancer: phase I/Ib
At 2.0 mg/kg Q2W:
HER2-high ~ HER2-low.
IHC2+/FISH- > IHC1+
Half-life of the ADC: 30 h
Half-life of MMAE released from the ADC: 60 h.”
Proceed to the article.
Source: Paolo Tarantino/X and Raffaele Colombo/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research. .
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
